GlassScriptPhysician profile
Hussaina Saria
NPI 1942349956
$3,004.60
in general payments reported to CMS, 2019-2025
30 companies · $819 in 2025
The $819 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.91 · 2020: $240 · 2021: $383 · 2022: $272 · 2023: $372 · 2024: $888 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767 · Education: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,766.68 |
| Education | $311.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $428.36 | 2021-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $278.75 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $234.36 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biohaven Pharmaceutical Holding Company LTD. | $224.81 | 2022 | |
| Biogen, INC. | $215.81 | 2020-2025 | Vumerity, Avonex, Plegridy |
| Amgen INC. | $210.41 | 2021-2025 | Uplizna |
| Abbvie INC. | $164.19 | 2021-2025 | Qulipta |
| Amneal Pharmaceuticals LLC | $111.86 | 2023-2025 | Rytary, Ongentys, Ongentys 50mg Capsules 30 |
| Lilly USA, LLC | $108.49 | 2020-2025 | Emgality, Reyvow, Amyvid |
| Livanova USA, INC. | $108.22 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Pfizer INC. | $100.92 | 2023-2025 | |
| Sk Life Science, INC. | $98.98 | 2021-2025 | |
| Neurelis, INC. | $98.60 | 2020-2025 | Valtoco |
| Ucb, INC. | $87.73 | 2021-2025 | Rystiggo |
| Vanda Pharmaceuticals INC. | $63.85 | 2024-2025 | Ponvory |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $54.51 | 2025 | |
| Genentech USA, INC. | $52.98 | 2025 | Ocrevus Zunovo |
| Neurocrine Biosciences, INC. | $50.83 | 2021-2025 | |
| Tg Therapeutics, INC. | $50.28 | 2024-2025 | |
| Argenx US, INC. | $36.26 | 2024 | Vyvgart Hytrulo |
| Horizon Therapeutics Plc | $34.55 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $34.15 | 2024 | |
| Medtronic, INC. | $27.38 | 2021-2025 | Inceptiv |
| Tanabe Pharma America, INC. | $24.97 | 2020 | |
| Banner Life Sciences, LLC | $23.23 | 2024 | |
| Acadia Pharmaceuticals INC | $21.02 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.76 | 2020 | |
| Avanir Pharmaceuticals, INC. | $15.23 | 2021 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Allergan, INC. | $11.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hussaina Saria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.